awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q43515124-E4A942F1-6595-4D47-A2AF-98ADC07BEBE0
Q43515124-E4A942F1-6595-4D47-A2AF-98ADC07BEBE0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43515124-E4A942F1-6595-4D47-A2AF-98ADC07BEBE0
Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.
P2860
Q43515124-E4A942F1-6595-4D47-A2AF-98ADC07BEBE0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q43515124-E4A942F1-6595-4D47-A2AF-98ADC07BEBE0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
8e337e0d517205ef7a3f9ab40008c5b67c3d0853
P2860
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the Nati